What are some challenges with CAR T-cell therapy in r/r MM that you’ve experienced in your clinical practice? What are some potential resources and/or strategies to help support logistical challenges or early referral?
What is the role of bridging therapy prior to CAR T-cell therapy?
How do you define “bridging therapy”?
What is the potential role of Selinexor as bridging therapy, and how have you incoporated it in your practice?